Introduction: Methamphetamine use is a serious public health concern in many countries
and is second to cannabis as the most widely abused illicit drug in the world. Effective …

Objectives To examine the safety of an agonist-type treatment, lisdexamfetamine (LDX), at
250 mg/day among adults with methamphetamine (MA) dependence. Design A dose …

As terapias cognitivo-comportamentais têm sido referenciadas como abordagens eficazes
no tratamento de diversos transtornos psiquiátricos–entre eles, os transtornos por uso de …

The first edition of these guidelines was published in 2007, and outlined acute and longer-
term interventions for methamphetamine use problems available at the time. Recent …

Introduction Methamphetamine dependence is a growing public health concern. There is
currently no pharmacotherapy approved for methamphetamine dependence …

Background and aims Cocaine use is prevalent among people receiving injectable opioid
agonist treatment. Investigations of cocaine use in this population have been descriptive and …

There are no approved pharmacotherapies for methamphetamine use disorder. Two
preliminary phase 2 randomised controlled trials have found mirtazapine, a tetracyclic …

Background: The abuse of methamphetamine (MA) worldwide has gained international
attention as the most rapidly growing illicit drug problem. The classification and treatment …

赖右苯丙胺(LDX) 是右旋苯丙胺(DXA) 的前体药物, 在血液中被水解生成赖氨酸和DXA,
并通过DXA 的活性形式发挥药理作用. LDX 已被美国FDA 批准用于治疗注意缺陷与多动障碍 …

The available treatments for substance use disorders (SUD) involving nicotine, cannabis,
caffeine, hallucinogens, psychostimulants, hydrocarbon-based inhalants and new …